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The murine gammaherpesvirus MHV-68 multiplies in the respiratory epithelium after intranasal inocula-
tion, then spreads to infect B cells in lymphoid germinal centers. Exposing B cells to MHV-68 in vitro caused
an increase in cell size, up-regulation of the CD69 activation marker, and immunoglobulin M (IgM) produc-
tion. The infectious process in vivo was also associated with increased CD69 expression on B cells in the
draining lymph nodes and spleen, together with a rise in total serum Ig. However, whereas the in vitro effect
on B cells was entirely T-cell independent, evidence of in vivo B-cell activation was minimal in CD41 T-cell-
deficient (I-Ab2/2) or CD41 T-cell-depleted mice. Furthermore, the Ig present at high levels in serum was
predominantly of the IgG class. Surprisingly, the titer of influenza virus-specific serum IgG in previously
immunized mice fell following MHV-68 infection, suggesting that there was relatively little activation of
memory B cells. Thus, CD41 T cells seemed both to amplify a direct viral activation of B cells in lymphoid
tissue and to promote new Ig class switching despite a lack of obvious cognate antigen.
Herpesvirus (HV) infections are often associated with non-
antigen-specific B-cell activation (13, 14, 16, 21, 22). Although
no definite role has been established for this process in viral
pathogenesis, it is of particular interest in gammaherpesvirus
(g-HV) infections, since chronic B-cell stimulation may con-
tribute to the oncogenesis (9, 15) associated with Epstein-Barr
virus (EBV) and human herpesvirus 8 (HHV-8) infections.
Infection with EBV activates B cells expressing the immuno-
globulin (Ig) V4-34 gene (4), which is also overrepresented in
certain lymphomas (6, 25). EBV-activated V4-34-expressing B
cells can undergo somatic mutation and isotype switching, in-
dicating a participation in normal germinal-center interactions
(5). The latent membrane protein 1 (LMP-1) of EBV, which
has intracellular signaling substrates similar to those of CD40
(12), and LMP-2A, which can trigger lymphocyte activation
(2), may both contribute to this process. However, analysis of
lymphocyte interactions in vivo has not been possible with the
human g-HVs.
The murine g-HV-68 (MHV-68) is a natural g-HV of small
rodents that is related to EBV (8) and to HHV-8 (33). After
intranasal (i.n.) infection of conventional mice, the virus
spreads from the lung to the lymphoid tissue (29) and then
persists in B lymphocytes (28) and in epithelial cells (27). This
persistent infection is associated with an infectious mononu-
cleosis-like illness (7, 20) characterized by a CD4-dependent
splenomegaly and an increase in viral load (31). In BALB/c
mice, MHV-68 causes an acute and apparently non-antigen-
specific rise in total serum IgG (26). The virus-specific serum
antibody response is, in contrast, relatively slow in onset and
does not reach plateau levels until 2 to 3 months after infection
(26). MHV-68-infected C57BL/6J (B6) mice have more IgG1
cells and fewer IgM1 cells in the spleen (18) than uninfected
controls, but to what extent this represents normal immunity is
unclear.
There is evidence (3) of MHV-68 infection in splenic ger-
minal centers, and both the non-antigen-specific B-cell activa-
tion and the CD4-dependent increase in viral load may reflect
an exploitation by the virus of normal germinal-center func-
tion. The present analysis defines the need, or lack thereof, for
CD41 T-cell help to drive B-cell activation following in vitro or
in vivo exposure to MHV-68.
MATERIALS AND METHODS
Mice, virus infection, and sampling. The B6, (B6 3 129)F1, CD40 ligand-
deficient (CD1542/2) (10), and interleukin 6 (IL-6)-deficient mice (IL-62/2)
(17) were purchased from Jackson Laboratories (Bar Harbor, Maine). The major
histocompatibility complex (MHC) class II-deficient mice (I-Ab2/2) that lack
CD41 T cells (11) were bred at St. Jude Children’s Research Hospital. Except for
i.n. infection with 600 PFU of MHV-68, all mice were kept under specific-
pathogen-free conditions. Virus stocks were grown in owl monkey kidney cells
(29), were free of contamination with lipopolysaccharide (LPS) (final concen-
tration, ,0.1 pg/ml) as determined by enzyme-linked immunosorbent assay
(ELISA) (BioWhittaker, Walkersville, Md.), and were negative for mycoplasma
by PCR ELISA (Boehringer Mannheim, Indianapolis, Ind.). Serum samples
were obtained either from the axillary artery after terminal anesthesia or from a
tail vein. Bone marrow was harvested, where indicated, from both femurs and
tibiae.
Cell cultures. Spleens from naive mice were homogenized to single-cell sus-
pensions (2 3 107/ml) in RPMI (Life Technologies, Grand Island, N.Y.) sup-
plemented (complete medium) with penicillin (60 mg/ml), glutamine (2 mM),
10% fetal calf serum (HyClone, Logan, Utah), and 55 mM 2-mercaptoethanol
and were exposed for 1 h at 37°C to infectious virus (0.1 PFU/cell) or to an
equivalent quantity of virus that had previously been heated for 3 h at 56°C to
abolish infectivity (PFU count per milliliter , 0.01% that of untreated virus).
After infection, the cells were washed once and cultured (3 3 106/ml) for 3 days
in complete medium at 37°C with 5% CO2. Control spleen cell populations were
cultured in complete medium alone and in complete medium with 10 mg of
LPS/ml (Sigma Chemical Co., St. Louis, Mo.).
Flow cytometry. Lymphocyte populations were washed in ice-cold phosphate-
buffered saline (PBS) with 0.01% azide and 0.1% bovine serum albumin, stained
on ice for 30 min with monoclonal antibodies (MAbs) to CD19, B220, and CD69
(Pharmingen, San Diego, Calif.), washed once more, and analyzed on a FAC-
Scan with Cellquest software (Becton Dickinson, San Jose, Calif.). Purified B
lymphocytes were obtained from unfractionated spleen cells by flow cytometric
sorting of B2201 CD191 cells on a FACStar Plus (Becton Dickinson). These
cells (.99% B2201 CD191) were stimulated and cultured as described for
unsorted spleen cells.
Total Ig and virus-specific Ig assays. Total IgG and IgM levels in serum and
culture supernatants were assayed as described previously (26). Briefly, Nunc
Maxisorp immunoplates (Fisher Scientific, Pittsburgh, Pa.) were coated over-
night at 4°C with goat anti-mouse IgG or goat anti-mouse IgM m chain (Sigma)
at 1 mg/ml in PBS. Plates were washed five times with PBS-Tween (0.05%),
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blocked for 1 h with PBS-Tween (0.05%)-bovine serum albumin (1%), incubated
with threefold dilutions of serum or culture supernatant for 1 h, and washed five
times. Bound antibody was detected with alkaline phosphatase-conjugated goat
anti-mouse IgG g chain (Sigma) or alkaline phosphatase-conjugated goat anti-
mouse IgM m chain (Sigma), by using a nitrophenylphosphate substrate (Sigma)
and reading the absorbance at 405 nm on a model 3550 Microplate Reader
(Bio-Rad, Hercules, Calif.).
Virus-specific IgG was assayed as for total IgG, except that plates were coated
with Triton X-100 (0.05%)-disrupted MHV-68 or influenza A/HKx31 virus.
MHV-68-specific neutralizing antibody was detected by a plaque reduction assay
(26). Briefly, twofold serum dilutions in minimal essential medium (Life Tech-
nologies) were incubated with 50 PFU of MHV-68 on ice for 1 h in 96-well
plates. Then 3 3 104 BALB/c-3T3 cells (American Type Culture Collection,
Manassas, Va.) were added to each well and, after a 6-h adherence, overlaid with
minimal essential medium containing 10% fetal calf serum and 0.75% carboxy-
methyl cellulose. After 4 days of culture the cells were fixed with methanol and
stained with Giemsa solution (Sigma). The neutralization titer was defined as the
highest serum dilution giving a .50% reduction in the number of viral plaques.
Sera from uninfected mice had no effect on plaque formation. The IgG- and
IgM-secreting plasma cells were detected with the same coating and detecting
antibodies used for the respective ELISAs, but with nitrocellulose-bottom 96-
well plates (Millipore, Bedford, Mass.). After anti-Ig-coated plates were blocked
with complete medium for 1 h, cultured cells were washed three times in com-
plete medium and incubated for 4 h at 37°C with 5% CO2. Spots visualized with
5-bromo-4-chloro-3-indolylphosphate toluidinium (BCIP)–nitroblue tetrazolium
(NBT) substrate (Sigma) were counted microscopically.
RESULTS
MHV-68 infection in vitro. Infection of naive spleen cells in
vitro with MHV-68 caused a dramatic activation of B cells,
manifested on flow cytometry as an increase in forward scatter
(cell size) and an up-regulation of the early activation marker
CD69 on the CD191 population (Fig. 1A). The effect of LPS
treatment is shown for comparison. The MHV-68-induced ac-
tivation profile was not due to contaminating endotoxin, since
this was undetectable in the virus preparation and would not
have been inactivated by the heat treatment regime (see Ma-
terials and Methods). There was also evidence of B-cell pro-
liferation: cell numbers were typically increased two- to three-
fold by 2 days after infection, and .90% of the B2201 cells
were in S phase as shown by propidium iodide staining (data
not shown). However, by day 5 of culture, .90% of the B cells
were shown to be apoptotic by propidium iodide staining (data
not shown), and we were not able to grow transformed B-cell
lines from these cultures.
The in vitro infection of naive spleen cells had no effect on
T-cell phenotype, as assessed by cell size, CD69 expression, or
CD62L expression (data not shown), suggesting that B-cell
activation was a direct viral effect rather than a result of lym-
phocyte interactions. The activation of flow cytometrically
sorted B cells (.99% B2201 CD191) by MHV-68 was equally
marked (Fig. 1B), indicating that it was an entirely T-cell-
independent phenomenon. The absence of any requirement
for CD41 T-cell help was further confirmed by a degree of
B-cell activation in spleen cell populations from CD41 T-cell-
deficient (I-Ab2/2) or CD40 ligand-deficient (CD1542/2) mice
equivalent to that in normal controls (Table 1). Although IL-6
production is prominent in spleen cultures after MHV-68 in-
fection (24), B-cell activation occurred to an equal extent in
FIG. 1. B-cell activation after in vitro exposure to MHV-68. Live lymphocytes were gated initially on the basis of forward and side scatter, then on the CD191
population. In each panel, the specifically treated population (bold line) is compared with control, untreated cells (lightface line). (A) Profile for spleen cells; (B) profile
for parallel cultures of flow cytometrically sorted B cells (.99% B2201 CD191). Equivalent results were obtained in five further experiments.
TABLE 1. CD69 expression on CD191 B cells after
in vitro MHV-68 infectiona
Genetic
background
Valueb for:
Uninfected cells MHV-68-infected cells
B6
I-Ab1/1 3.8 43.2
I-Ab2/2 3.4 35.8
B6 3 129
CD1541/1 Il-61/1 14.4 79.3
CD1542/2 9.1 71.4
IL-62/2 11.9 76.4
B6
Untreated 16.8 185.6
1 Anti-IL6 MAb ND 201.6
1 Isotype control MAb ND 162.3
a Spleen cells either were not infected or were infected with MHV-68 at 0.1
PFU/cell, then cultured (3 3 106/ml) for 3 days. Live lymphocytes were gated by
forward and side scatter, and B cells were identified by further gating on the
CD191 population. In all cases there was significant up-regulation of CD69
expression on the CD191 population following MHV-68 infection (p , 0.0001 by
Kolmogorov-Smirnov statistics). Each set of results is representative of two
experiments.
b Geometric mean fluorescence intensity of anti-CD69–fluorescein isothiocya-
nate staining. ND, not done.
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spleen cells from IL-6-deficient mice or in cultures incorporat-
ing a neutralizing MAb to IL-6 (Pharmingen), added daily at
10 mg/ml (Table 1). Thus, IL-6 did not play a central role in
mediating the virus-induced B-cell activation. Furthermore,
the absence of this cytokine has no obvious effect on the patho-
genesis of infection (23). The MHV-68 genome is not known to
encode a viral analogue of IL-6 (33).
The in vitro infection protocol also stimulated Ig production,
which was detectable from 2 days after infection by ELISA of
culture supernatants (Fig. 2A). The Ig detected was predomi-
nantly of the IgM class, and ELISpot assays (Fig. 2B) con-
firmed that almost all (.99%) of the antibody-forming cells
(AFCs) produced IgM rather than IgG. Thus, although B cells
were activated and differentiated to AFCs after exposure to
MHV-68 in vitro, there was no significant Ig class switching,
even in the presence of CD41 T cells.
MHV-68 infection in vivo. Giving MHV-68 i.n. to B6 mice
caused a sustained, approximately fourfold increase in total
serum Ig titers (Fig. 3A and B). In contrast to the situation in
vitro, IgG was the major component of the increased serum Ig
levels (Fig. 3B). At day 16 after infection, t tests showed sig-
nificant rises in both serum IgG (P , 0.0001) and IgM (P ,
0.0005) levels in the B6 mice relative to uninfected controls.
There was no significant rise in serum IgG in the I-Ab2/2 mice
(P . 0.1), but the relatively small rise in IgM was significant
(P , 0.01). Virus-specific serum Ig (Fig. 3C and D) was un-
detectable in the I-Ab2/2 mice and showed a rather gradual
rise in the B6 mice. The results for B6 mice were consistent
with those described previously for the BALB/c strain (26).
The extent of B-cell activation after MHV-68 infection of B6
mice was also evident from the massive increase in CD69
expression on this lymphocyte population in the draining
lymph nodes and, to a lesser degree, in the spleen (Fig. 4). This
effect was only minimally evident in the CD41 T-cell-deficient
I-Ab2/2 mice.
It is known that EBV uses HLA-DR as a cofactor for entry
into B cells (19). However, the relative lack of B-cell activation
after MHV-68 infection of I-Ab2/2 mice was shown not to
result from the absence of MHC class II glycoprotein on the B
cells, by using adult thymectomized B6 mice that were de-
pleted of CD41 T cells by MAb treatment prior to infection.
These CD41 T-cell-depleted mice showed no rise in total se-
rum IgG levels compared to uninfected controls (Fig. 5).
Mice that had been immunized i.n. 2 to 3 months previously
with the influenza A/HKx31 virus were infected with MHV-68
to determine the effect on established B cells that had already
switched to IgG production. Surprisingly, there was a signifi-
cant fall in the titer of influenza virus-specific IgG in serum
after MHV-68 infection (Fig. 6), suggesting that IgG-switched
FIG. 2. Ig production by B cells after exposure to MHV-68 in vitro. (A)
ELISA absorbance values are shown for threefold dilutions of culture superna-
tants from LPS-treated (E), MHV-68-infected (F), and untreated (h) cultures
of flow cytometrically purified B cells, by using plates coated with affinity-purified
anti-IgG or anti-IgM Ig. Selective IgM secretion was also observed with unfrac-
tionated spleen cell cultures (data not shown). Equivalent results were obtained
in five further experiments. (B) ELISpot assay results. Means 6 SD of quadru-
plicates are shown for unfractionated spleen cell cultures, by using nitrocellulose-
bottom wells coated with affinity-purified antisera specific for either mouse IgG
or mouse IgM. The number of IgM-producing AFCs was significantly increased
in the LPS- and MHV-68-treated populations (P , 0.0001 by t test). Equivalent
results were obtained in two further experiments and also with flow cytometri-
cally purified B cell cultures.
FIG. 3. Virus-specific and total serum antibody levels after MHV-68 infec-
tion. Each point shows the mean titers (6 SD) for six individual B6 (E) or
I-Ab2/2 (F) mice. The total serum IgM, total serum IgG, and total virus-specific
serum IgG were determined by ELISA, while the neutralizing virus-specific
antibody titer was determined by plaque inhibition (see Materials and Methods).
All measurements were made with reference to a standard immune serum, and the
titers are expressed as arbitrary units.
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memory B cells were not contributing to the acute rise in total
serum IgG. No significant loss of influenza A/HKx31 virus-
specific plasma cells was apparent in the bone marrow of the
MHV-68-infected mice: in one of three equivalent experi-
ments, the numbers of influenza A/HKx31 virus-specific AFCs/
105 bone marrow cells (means 6 standard deviations [SD]; six
mice per group) were 146 6 44 with influenza A/HKx31 virus
alone and 125 6 53 with influenza A/HKx31 virus followed by
MHV-68.
We then asked whether the relative fall in the influenza
virus-specific Ig titer reflected simple dilution due to an in-
creased rate of production of new Ig specificities. The decay in
the titer of Sendai virus-specific IgG in serum was monitored
over 30 days in mice given a bolus intravenous injection of a
Sendai virus-specific IgG2a MAb (500 mg/mouse) at the same
time as mock infection or infection with MHV-68. No differ-
ence (mean 6 SD for six individuals per group) in IgG turn-
over (32) was observed between uninfected mice (half-life 5
8.5 6 3.2 days) and MHV-68-infected mice (half-life 5 10.0 6
1.6 days). A possible implication is that factors promoting
continued Ig production by the influenza virus-specific memory
B cells were in some way compromised by the MHV-68 infec-
tion.
DISCUSSION
Exposing splenic B cells to a relatively high dose of MHV-68
in vitro led to generalized B-cell activation, independent of a
contribution from other cell types. In contrast, in vivo B-cell
activation was considerably reduced in congenitally CD41 T-
cell-deficient or CD41 T-cell-depleted mice compared with
that in immunocompetent controls. This difference could indi-
cate that the MHV-68 viral load is limiting in vivo and that
CD41 T-cell-dependent proliferation of the activated, virus-
infected B cells is required to achieve a significant effect. It may
also be the case that CD41 T cells provide survival signals to
the activated B cells, as the CD41 T-cell-independent prolif-
erative stimulus provided to B cells in vitro by MHV-68 infec-
tion rapidly led to apoptosis.
An interesting feature of the in vitro B-cell stimulation was
a lack of clear dependency on virus dose, with equivalent
activation being observed for a range of 0.01 to 10 PFU/cell
(data not shown). Essentially all the B cells were activated,
despite the presence of little infectious virus (,1 PFU/104 cells
by plaque assay), suggesting that uninfected B cells were also
being induced, perhaps by a specific viral protein. Whatever
the mechanism, the net effect seems to be that in vivo MHV-68
infection activates B cells such that they can interact with
CD41 T cells independently of normal antigenic stimulation.
One obvious question concerns the source of the “helper”
CD41 T cells that might be involved. Although massive T-cell
activation is a prominent feature of MHV-68 infection in vivo
FIG. 4. Flow-cytometric analysis of B-cell phenotypes from spleens and me-
diastinal lymph nodes (MLN) of B6 and I-Ab2/2 mice after MHV-68 infection.
Live lymphocytes were gated by forward and side scatter, and B cells, further
gated on the basis of B220hi staining, were divided into CD69lo (E) or CD69hi
(F) subsets. Both CD69hi B220hi and CD69lo B220hi cells were uniformly CD191
(data not shown). Cells were pooled from one to three mice for each time point.
The numbers of each cell type per mouse were calculated from the total cell
counts and the proportions stained specifically by flow cytometry. Each point
shows the mean 6 SD of two to six pools.
FIG. 5. Serum IgG levels in intact and CD4-depleted mice. Adult thymecto-
mized mice were depleted of CD41 T cells by five injections of ascitic fluid
containing the GK1.5 MAb at days 24 to 14 relative to i.n. virus challenge (1).
Flow-cytometric staining of spleen cells at the time of sampling, 19 days after
MHV-68 infection, indicated that depletion was .95%. Mean absorbance values
(6 SD) are shown for threefold serum dilutions from three individual thymec-
tomized mice, either undepleted and MHV-68 infected (F), undepleted and
uninfected (h), or CD4 depleted and MHV-68 infected (E). An equivalent
CD81 T-cell depletion protocol did not reduce the elevation of total serum IgG
levels (data not shown). These results were reproduced in a repeat experiment.
FIG. 6. Influenza virus-specific serum IgG titers in influenza virus-immune
B6 mice after MHV-68 infection. Mice primed i.n. with 30 hemagglutination
units of influenza A/HKx31 virus were challenged i.n. 2 months later with 600
PFU of MHV-68 (F) or were left untreated (E). Each point shows the mean titer
(6 SD) from six individuals per group. The same mice were bled (30 to 50 ml per
sample) serially from a tail vein. A standard immune serum was included on each
ELISA plate to allow for comparison between samples. The influenza A/HKx31
(H3N2) virus that was used to prime the mice 8 to 12 weeks prior to the challenge
with MHV-68 was also used as the immunoabsorbent. The titers of influenza
virus-specific serum IgG were significantly lower (P , 0.0002 by t test) in MHV-
68-infected mice at days 21, 28, and 38 than in uninfected control mice. Equiv-
alent results were obtained in two further experiments.
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(7), the lack of an effect on CD41 T cells in vitro and the
absence of an obvious T-cell receptor Vb bias in the CD41 (as
distinct from CD81) population (30) argue against a superan-
tigen effect. Instead, the fact that the in vivo interaction be-
tween CD41 T cells and virus-infected B cells was not repro-
duced in cell culture implied that a distinct source of activated
CD41 T cells was required, perhaps even the normal, antigen-
specific CD41 T-cell response (26).
The Ig class switching presumably occurred at the same time
as B-cell activation and may reflect a component of normal
germinal-center function in an essentially virus-driven process.
An important prediction of this model is that virus should be
found in Ig class-switched, memory B cells that may also show
evidence of somatic hypermutation. We have not, at this stage,
identified an appropriate surface antigen that would allow us
to separate such infected B cells for genetic analysis.
Since non-antigen-specific B-cell activation occurs with both
B-cell-tropic (16, 22) and non-B-cell-tropic (13, 14, 21) HV
infections, it may also represent a means exploited by the virus
to inhibit the normal humoral response. It is notable in this
regard that the MHV-68-specific serum Ig response (26) is
slow to reach plateau levels (Fig. 3C and D). The experiments
with influenza virus-immune mice (Fig. 6) suggested that
plasma cell function is somehow suppressed during the poly-
clonal activation, possibly due to massive cytokine release.
Clearly any such suppression could also affect the MHV-68-
specific response, thus promoting viral dissemination and per-
sistence.
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